Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.
Daveson AJM, Stubbs R, Polasek TM, Isola J, Anderson R, Tye-Din JA, Schoeman M, Lionnet C, Mei SLCY, Mihajlović J, Wirth M, Peelen E, Schreieck A, Kohlhof H, Vitt D, Muehler A, Buriánek F. Daveson AJM, et al. Among authors: kohlhof h. Lancet Gastroenterol Hepatol. 2025 Jan;10(1):44-54. doi: 10.1016/S2468-1253(24)00248-6. Epub 2024 Nov 7. Lancet Gastroenterol Hepatol. 2025. PMID: 39521016 Clinical Trial.
Orally bioavailable RORγ/DHODH dual host-targeting small molecules with broad-spectrum antiviral activity.
Herrmann A, Gege C, Wangen C, Wagner S, Kögler M, Cordsmeier A, Irrgang P, Ip WH, Weil T, Hunszinger V, Groß R, Heinen N, Pfaender S, Reuter S, Klopfleisch R, Uhlig N, Eberlein V, Issmail L, Grunwald T, Hietel B, Cynis H, Münch J, Sparrer KMJ, Ensser A, Tenbusch M, Dobner T, Vitt D, Kohlhof H, Hahn F. Herrmann A, et al. Among authors: kohlhof h. Antiviral Res. 2024 Nov;231:106008. doi: 10.1016/j.antiviral.2024.106008. Epub 2024 Sep 19. Antiviral Res. 2024. PMID: 39306285 Free article.
Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis: Extended Results of a Placebo-Controlled Phase 2 Trial.
Fox RJ, Wiendl H, Wolf C, De Stefano N, Sellner J, Gryb V, Rejdak K, Bozhinov PS, Vitt D, Kohlhof H, Slizgi J, Ondrus M, Sciacca V, Muehler AR; EMPhASIS investigators. Fox RJ, et al. Among authors: kohlhof h. Neurol Neuroimmunol Neuroinflamm. 2024 May;11(3):e200208. doi: 10.1212/NXI.0000000000200208. Epub 2024 Apr 25. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 38662979 Free PMC article. Clinical Trial.
88 results